Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab Ozogamicin in R/R CD22+ ALL
NCT01363297Phase 2Completed
- Sponsor
- Pfizer
- Start
- Aug 2011
- Primary completion
- Aug 2014
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL), sponsored by Pfizer. Primary endpoints: Dose Limiting Toxicities at Cycle 1, Preliminary Satisfactory Response (CR, CRi, PR, RD) up to 2 years and 2 more. Started Aug 2011; status: completed.
02
Drugs
inotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01363297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01363297.